Compare Autodesk Inc (ADSK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autodesk Inc vs BIO-TECHNE Corp — how do they compare? Autodesk Inc trades at $251.75 (market cap $54.07B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Autodesk Inc is far larger — about 4.8× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Autodesk Inc pays none. Which is the better fit depends on your goals.
| ADSK | TECH | |
|---|---|---|
Market Cap | $54.07B | $11.24B |
Sector | Technology | Health |
52-Week High | $326.79 | $72.29 |
52-Week Low | $187.72 | $43.31 |
Enterprise Value | $53.87B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $249.08, up 2.73% on the day, with a bullish technical signal and strong fundamental performance. Revenue grew to $6.13B in 2025, with net income reaching $1.11B and a 19.49% net margin. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $2.99 exceeding the $2.84 forecast. Analyst consensus is a Buy with a $305.31 price target, supported by 74.51% of analysts rating it a Buy. Recent news highlights AI investments and strategic acquisitions.
Outlook remains positive given robust earnings growth, high profitability margins, and strategic AI investments. Risks include competitive pressures in software, reliance on economic cycles affecting design software demand, and execution risks from recent acquisitions. The stock offers upside to the consensus target but faces volatility near technical resistance at $253.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
